Tag: ASX: ALA
Arovella’s ALA-101 inches toward clinic following key manufacturing achievement
Arovella Therapeutics Ltd, the biotechnology company specialising in iNKT cell therapy, announced that the Good Manufacturing Practice (GMP)-grade lentiviral vector for its lead product, ALA-101, has completed successful manufacturing and quality release testing.
Featured Article
The future of sports manufacturing: Inside M2M Group’s AI-powered strategy
As the sports manufacturing industry evolves, artificial intelligence (AI) is emerging as a critical catalyst for innovation and efficiency.
